Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Taysha Gene Therapies, Inc.’s reported figures.
The source filing: Taysha Gene Therapies, Inc.’s 10-Q, filed August 11, 2026. Open the filing →
- Filed
- Aug 11, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344610
FAQ
- What is Taysha Gene Therapies, Inc.'s EBIT?
- Taysha Gene Therapies, Inc. (TSHA) reported EBIT of -$47.35M in Q2 2026.
- How has Taysha Gene Therapies, Inc.'s EBIT changed year-over-year?
- Taysha Gene Therapies, Inc.'s EBIT decreased by 77.0% year-over-year, from -$26.75M to -$47.35M.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s EBIT?
- Over 4 years (2021 to 2025), Taysha Gene Therapies, Inc.'s EBIT has grown at a -10.6% compound annual growth rate (CAGR), from -$173.27M to -$110.5M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Taysha Gene Therapies, Inc.'s ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude